Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Dermatology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjd.12110PMID 23106107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

  2012cited by this paper
• Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

  2012cited by this paper
• Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study

  2012cited by this paper
• Pivotal Role of Dermal IL-17-Producing ?d T Cells in Skin Inflammation

  2011cited by this paper
• Latitude and psoriasis prevalence.

  2011cited by this paper
• Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.

  2011cited by this paper
• Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

  2010cited by this paper
• IL‐17‐producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17‐related cytokines

  2009cited by this paper
• Mechanisms of Disease: Psoriasis.

  2009cited by this paper
• Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.

  2008cited by this paper
• The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis

  2007cited by this paper
• Pathogenesis and therapy of psoriasis

  2007cited by this paper
• Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.

  2005cited by this paper
• Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

  2005cited by this paper
• A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

  2005cited by this paper
• Severe psoriasis--oral therapy with a new retinoid.

  1978cited by this paper

• The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa

  2025cites this paper
• A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis

  2025cites this paper
• Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis

  2025cites this paper
• Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis

  2025cites this paper
• Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

  2025cites this paper
• IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study

  2025cites this paper
• Advances in dermatology research: A comprehensive literature review

  2025cites this paper
• Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis

  2025cites this paper
• Saturated fatty acid-induced neutrophil extracellular traps contribute to exacerbation and biologic therapy resistance in obesity-related psoriasis

  2025cites this paper
• Association Between Psoriasis Risk and Body Mass Index and Waist Circumference in Diabetes: A Population-Based Cohort Study

  2025cites this paper
• Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients

  2025cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2025influential citation
• Verlängerung der Dosierungsintervalle von IL‐17‐ und IL‐23‐Inhibitoren bei erwachsenen Patienten mit Psoriasis: eine Pilotstudie aus der Praxis

  2025cites this paper
• [Influence of long-term biologic therapy on metabolic biochemical parameters in moderate to severe plaque psoriasis].

  2025cites this paper
• Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis

  2025cites this paper
• The impact of IL-17A inhibitors on scalp and gut microbiota in psoriasis

  2025cites this paper
• IL-17 as a Therapeutic Target in Cardiovascular Diseases: Mechanistic Insights and Translational Opportunities.

  2025cites this paper
• Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review

  2025influential citation
• Exploring the Therapeutic and Gut Microbiota-Modulating Effects of Qingreliangxuefang on IMQ-Induced Psoriasis

  2025cites this paper
• Systemic secukinumab treatment in patients with ankylosing spondylitis: the relationship between systemic and tear proinflammatory cytokines and ocular surface findings—a pilot study

  2025cites this paper
• Predictors of Successful Secukinumab Dose Tapering in Moderate-to-Severe Psoriasis: A Retrospective Study

  2025cites this paper
• Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies

  2025cites this paper
• Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials

  2024cites this paper
• Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis.

  2024cites this paper
• A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects

  2024cites this paper
• “I Was Almost in Disbelief” - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab

  2024cites this paper
• Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review.

  2024cites this paper
• The Perspective of Cannabidiol in Psoriasis Therapy

  2024cites this paper
• The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity

  2024cites this paper
• Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing

  2024cites this paper
• Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.

  2024cites this paper
• Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis

  2023cites this paper
• The selection of the initial drug in the treatment of severe psoriasis

  2023cites this paper
• Targeted Treatment of Diseases of Immune Dysregulation.

  2023cites this paper
• Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta‐analysis of randomized controlled trials

  2023cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2023cites this paper
• Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

  2023cites this paper
• Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment.

  2023cites this paper
• Oroxylin A inhibited autoimmune hepatitis-induced liver injury and shifted Treg/Th17 balance to Treg differentiation

  2023cites this paper
• Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States

  2023cites this paper
• Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study

  2023cites this paper
• A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents

  2023cites this paper
• Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report

  2023cites this paper
• Comparative Analysis of the Therapeutic Effects of Fresh and Cryopreserved Human Umbilical Cord Derived Mesenchymal Stem Cells in the Treatment of Psoriasis

  2023cites this paper
• Importance and prospects of studying survival of genetically engineered biological therapy for psoriasis in children

  2022cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2022cites this paper
• Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab

  2022cites this paper
• Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis

  2022cites this paper
• Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.

  2022cites this paper
• Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review

  2022cites this paper
• Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized Definition

  2022cites this paper
• Efficacy and safety of immune checkpoint inhibitors and cytokine therapy in autoimmune diseases

  2022cites this paper
• Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

  2022cites this paper
• Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis

  2022cites this paper
• Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study

  2022cites this paper
• Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry

  2022cites this paper
• Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis

  2022cites this paper
• Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

  2022cites this paper
• Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis

  2022cites this paper
• Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

  2022cites this paper
• Fast and sustained improvement of patient‐reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

  2022cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2021cites this paper
• Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial

  2021cites this paper
• Effectiveness of brodalumab after previous treatment failure of interleukin‐17A inhibitors in patients with psoriasis

  2021cites this paper
• Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial

  2021cites this paper
• Gastroenterological safety of IL-17 inhibitors: a systematic literature review

  2021cites this paper
• Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis.

  2021cites this paper
• Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.

  2021cites this paper
• Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534

  2021cites this paper
• Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials

  2021cites this paper
• Protein–protein interaction and in silico mutagenesis studies on IL17A and its peptide inhibitor

  2021cites this paper
• Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic Target

  2021cites this paper
• Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?

  2021cites this paper
• A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population

  2021cites this paper
• Hypertension

  2021cites this paper
• Anti IL-17 therapy rapidly decreases osteoclast activity in psoriatic patients: a novel quality in addition to its efficacy and safety.

  2021cites this paper
• Vergleich der Wirksamkeit und Sicherheit von Biologika bei mittelstark bis stark ausgeprägter Plaque‐Psoriasis: Metaanalyse multipler Therapien

  2021cites this paper
• Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

  2020cites this paper
• Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis.

  2020cites this paper
• Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review.

  2020cites this paper
• A review of secukinumab in psoriasis treatment.

  2020cites this paper
• Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE, a randomized, double‐blind, placebo‐controlled trial

  2020cites this paper
• Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis

  2020cites this paper
• Treatment Modalities of Psoriasis: A Focus on requisite for Topical Nanocarrier.

  2020cites this paper
• The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment

  2020cites this paper
• Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?

  2020cites this paper
• Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis.

  2020cites this paper
• Clinical trials in the BJD: reviewing the last decade and looking to the future

  2020cites this paper
• Title Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes

  2020cites this paper
• Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population

  2020cites this paper
• Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions

  2020cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2020cites this paper
• Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies

  2020cites this paper
• Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations

  2020cites this paper
• Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases: A review for future perspectives.

  2020cites this paper
• Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series

  2020cites this paper
• Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results

  2020cites this paper
• Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis

  2020cites this paper
• Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study *

  2020cites this paper
• Successful use of secukinumab in Netherton syndrome

  2020cites this paper